What initial therapy do you offer elderly patients with metastatic NSCLC with MET amplification and PD-L1 >50%?

For now, MET amplification does not impact my first-line therapy recommendations. MET amplification is a potential target - depending on how amplification is defined - particularly when mediating resistance. But the currently approved MET TKIs are for MET exon 14 mutations, not amplification. Immuno...

I agree with Dr. @Dr. First Last. I would do immunotherapy as well. I would add that if there is a high tumor burden, symptoms, and the need for quick response, I would add chemotherapy also to the regimen even though there is high PD-L1. If the patient never smoked, I would also be inclined to add ...